Homocysteine and Reclassification of Cardiovascular Disease Risk

被引:251
|
作者
Veeranna, Vikas [1 ,2 ]
Zalawadiya, Sandip K. [1 ,2 ]
Niraj, Ashutosh [1 ,2 ]
Pradhan, Jyotiranjan [1 ,2 ]
Ference, Brian [1 ,2 ]
Burack, Robert C. [2 ]
Jacob, Sony [1 ,2 ]
Afonso, Luis [1 ,2 ]
机构
[1] Wayne State Univ, Div Cardiol, Detroit Med Ctr, Detroit, MI 48201 USA
[2] Wayne State Univ, Dept Internal Med, Detroit Med Ctr, Detroit, MI 48201 USA
关键词
cardiovascular risk; homocysteine; risk reclassification; CORONARY-HEART-DISEASE; ARTERY CALCIUM SCORE; C-REACTIVE PROTEIN; FOLIC-ACID; SERUM HOMOCYSTEINE; PREDICTIVE-VALUE; ISCHEMIC-STROKE; PERFORMANCE; POPULATION; MORTALITY;
D O I
10.1016/j.jacc.2011.05.028
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives The purpose of this study was to examine whether adding homocysteine (Hcy) to a model based on traditional cardiovascular disease (CVD) risk factors improves risk classification. Background Data on using Hcy to reclassify individuals in various risk categories beyond traditional approaches have not been adequately scrutinized. Methods We performed a post hoc analysis of the MESA (Multi-Ethnic Study of Atherosclerosis) and NHANES III (National Health and Nutrition Examination Survey III) datasets. Hcy was used to predict composite CVD and hard coronary heart disease (CHD) events in the MESA study and CVD and CHD mortality in the NHANES III survey using adjusted Cox-proportional hazard analysis. Reclassification of CHD events was performed using a net reclassification improvement (NRI) index with a Framingham risk score (FRS) model with and without Hcy. Results Hcy level (>15 mu mol/l) significantly predicted CVD (adjusted hazard ratio [aHR]: 1.79, 95% confidence intervals [CI]: 1.19 to 1.95; p = 0.006) and CHD events (aHR: 2.22, 95% CI: 1.20 to 4.09; p = 0.01) in the MESA trial and CVD (aHR: 2.72, 95% CI: 2.01 to 3.68; p < 0.001) and CHD mortality (aHR: 2.61, 95% CI: 1.83 to 3.73; p < 0.001) in the NHANES III, after adjustments for traditional risk factors and C-reactive protein. The level of Hcy, when added to FRS, significantly reclassified 12.9% and 18.3% of the overall and 21.2% and 19.2% of the intermediate-risk population from the MESA and NHANES cohorts, respectively. The categoryless NRI also showed significant reclassification in both MESA (NRI: 0.35, 95% CI: 0.17 to 0.53; p < 0.001) and NHANES III (NRI: 0.57, 95% CI: 0.43 to 0.71; p < 0.001) datasets. Conclusions From these 2 disparate population cohorts, we found that addition of Hcy level to FRS significantly improved risk prediction, especially in individuals at intermediate risk for CHD events. (J Am Coll Cardiol 2011; 58: 1025-33) (C) 2011 by the American College of Cardiology Foundation
引用
收藏
页码:1025 / 1033
页数:9
相关论文
共 50 条
  • [1] Homocysteine and risk of cardiovascular disease
    Andreotti, F
    Burzotta, F
    Manzoli, A
    Robinson, K
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2000, 9 (01) : 13 - 21
  • [2] Homocysteine and Risk of Cardiovascular Disease
    Felicita Andreotti
    Francesco Burzotta
    Alessandro Manzoli
    Killian Robinson
    [J]. Journal of Thrombosis and Thrombolysis, 2000, 9 : 13 - 21
  • [3] Fitness and Reclassification of Risk for Cardiovascular Disease Mortality
    Gupta, Sachin
    Rohatgi, Anand
    Ayers, Colby R.
    Willis, Banjamin
    Haskell, William
    Khera, Amit
    Drazner, Mark H.
    de Lemos, James A.
    Berry, Jarett D.
    [J]. CIRCULATION, 2010, 122 (21)
  • [4] URIC ACID AND CARDIOVASCULAR DISEASE RISK RECLASSIFICATION
    Veeranna, Vikas
    Zalawadiya, Sandip
    Panaich, Sidak
    Kottam, Anupama
    Afonso, Luis
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (10) : E1333 - E1333
  • [5] Homocysteine as a risk factor for cardiovascular disease
    Graham, IM
    Meleady, R
    [J]. ATHEROSCLEROSIS XI, 1998, 1155 : 419 - 423
  • [6] Homocysteine as a risk factor in cardiovascular disease
    Cole, DEC
    [J]. DIABETES AND CARDIOVASCULAR DISEASE: ETIOLOGY, TREATMENT, AND OUTCOMES, 2001, 498 : 59 - 64
  • [7] Homocysteine as a risk factor of cardiovascular disease
    Merkel, M
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2003, 4 (02) : 97 - 98
  • [8] Chapter 8 Homocysteine and risk of cardiovascular disease
    Cooper, Gerald R.
    Pfeiffer, Christine M.
    [J]. ACTA BIOQUIMICA CLINICA LATINOAMERICANA, 2010, 44 (03): : 446 - 453
  • [9] HOMOCYSTEINE AS A RISK FACTOR FOR CARDIOVASCULAR-DISEASE
    GRAHAM, IM
    [J]. TRENDS IN CARDIOVASCULAR MEDICINE, 1991, 1 (06) : 244 - 249
  • [10] Is homocysteine an independent risk factor for cardiovascular disease?
    Domínguez-Rodríguez, A
    Abreu-González, P
    García-González, MJ
    Ferrer-Hita, J
    [J]. MEDICINA CLINICA, 2005, 125 (20): : 798 - 799